GlassScriptPhysician profile
Jill S Kimbrough
NPI 1932393410
$999.38
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $577 · 2020: $422.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $257.10 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $228.61 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $125.87 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $72.90 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $57.74 | 2019 | |
| Bausch Health US, LLC | $47.61 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $31.68 | 2019 | |
| Neurocrine Biosciences, INC. | $29.00 | 2019 | |
| Lundbeck LLC | $27.35 | 2019-2020 | |
| Neos Therapeutics, LP | $17.95 | 2020 | |
| Neuronetics, INC. | $16.90 | 2019 | |
| Shire North American Group INC | $16.38 | 2019 | |
| Adlon Therapeutics L.P. | $15.98 | 2019 | |
| Eisai INC. | $14.74 | 2020 | |
| Currax Pharmaceuticals LLC | $13.75 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $13.57 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $12.25 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jill Kimbrough listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.